NEW YORK, NY / April 08, 2020 / CLS Therapeutics, a privately held anticancer gene therapy platform company addressing a novel therapeutic target, announces presentation at the upcoming 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting that will be held from April 29 to May 2, 2019 that is planned to be held May 12 – May 15, 2020, at the Hynes Convention Center in Boston, USA.
A poster presentation named “First-In-Class AAV-Based Gene Therapy for Pancreatic Cancer and Other Tumors Based on the Destruction of Cell-Free DNA with Vector-Delivered DNase I” will showcase CLS’ data for the use of their CLS-014 drug candidate. CLS has identified a new therapeutic target (blood tumor- and neutrophils- derived cell-free DNA) for the successful anticancer therapy for multiple cancers and their initial indication is pancreatic cancer. Thus, CLS revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies (and has been independently confirmed by leading universities and research groups). The Company uses smart AAV technology for the delivery of gene to the liver, after which, hepatocytes in a 48 hours start to produce recombinant human enzyme that destroys this cell-free DNA.
The data that will be presented is exemplifies how CLS’ cutting-edge gene therapy capabilities can be leveraged to potentiate first-line chemotherapy, decrease primary tumor growth and prevent metastases formation in pancreatic cancer models. Furthermore, Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics, will be participating in the Scientific Symposiums.
Poster presentation details:
First-In-Class AAV-Based Gene Therapy for Pancreatic Cancer and Other Tumors Based on the Destruction of Cell-Free DNA with Vector-Delivered DNase I
George Tetz1, MD, PhD, Casey A Maguire3, PhD, Allan Tsung MD, Dmitry Genkin1 MD, Victor Tetz2 MD, PhD
1CLS Therapeutics Institute, New York, NY, 10013 USA
2Human Microbiological Institute, New York, NY, 10013 USA
3Molecular Neurogenetics Unit, Massachusetts General Hospital, Harvard Medical
4Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
Thursday May 14, 2020 5:30 PM – 6:30 PM
Session Title: Cancer – Targeted Gene and Cell Therapy
Room: Exhibit Hall C & D
Final abstract number: 1178
Abstracts will be also available on the ASGCT website. The poster presentations to be presented at the 2020 ASGCT Annual Meeting will be available on the CLS Therapeutics website after May 14, 2020.
Jenene Thomas Communications LLC
NEW YORK, NY / ACCESSWIRE / September 18, 2019 / CLS Therapeutics, a privately held oncology-focused gene therapy company developing a platform technology based on the identification of a novel therapeutic target that can be utilized for many cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CLS-014 for the treatment of pancreatic cancer.h.
NEW YORK, NY / May 14, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data on its AAV therapy clinical candidate, CLS-014, this week at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT).
NEW YORK, March 28, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Targeting Tumor Heterogeneity” being held on May 8, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed ) encoding DNase I of the treatment of pancreatic cancer animal model.